Pharmaceuticals
Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
* Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product * Phase I and II clinical trials completed. Phase III to be done in co-development with global partners. * Unique, Australian developed unique Patchless Patch™ delivery technolo...
2026-04-28 14:25
3500
BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE
Key Highlights: * An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues...
2026-04-28 10:17
4588
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan
TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan. SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, susta...
2026-04-28 09:00
4983
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces an educational webinar exploring the evolution of PSMA[1]-targeted radionuclide therapy and Telix's differentiated, multi-product approach to treating pros...
2026-04-28 07:44
6096
IMG Pharma Enters into Definitive Agreement to Acquire Matsumoto Pharmaceutical
TOKYO, April 27, 2026 /PRNewswire/ -- IMG Pharmaceutical Co., Ltd. ("IMG Pharma"), a majority-owned subsidiary of IMG Japan, the Group's holding company, announced that it has entered into a definitive agreement to acquire Matsumoto Pharmaceutical Co., Ltd., a Japanese pharmaceutical manufacturer...
2026-04-27 16:35
3913
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data from the Phase II study are expected in the third quarter of 2026. HONG KONG, April 27, 2026 /PRN...
2026-04-27 08:10
7235
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. These findi...
2026-04-26 19:00
7782
Daewoong Pharmaceutical Hosts 'NABOTA Master Class'… Highlighting Safety Amid Growing Demand for High-Dose, Repetitive Treatments
* 74 healthcare professionals from 13 countries attended, recognizing the value of PrabotulinumtoxinA's "Safety" * Comprehensive program including anatomy sessions, proprietary injection techniques, and 1:1 hands-on training * Global participants praise the program as "a platform to share pr...
2026-04-24 11:16
5373
Servier completes the acquisition of Day One Biopharmaceuticals
* Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. * Transaction also includes a strong oncology pipeline of clinical stage assetsin rare cancers with high unmet needs. * Transaction represents total equity ...
2026-04-23 20:30
4104
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-ne...
2026-04-23 16:22
6573
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...
2026-04-23 15:02
1631
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
SUZHOU, China, April 23, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative lo...
2026-04-23 10:19
1434
Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations
SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a next-generation subcutaneous (SC) delivery platform designed to simultaneously enhance the administration c...
2026-04-23 06:30
4402
Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA
BEIJING, April 22, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results...
2026-04-22 11:09
3124
NOVI Health's Hybrid Care Model Closes Gap Between Clinical Trials and Real-World GLP-1 Outcomes
An estimated ~14.7% weight loss at 18 months was achieved in one of the first studies evaluating integrated GLP-1 therapies and digital coaching in a multi-ethnic Asian population (n=708). This matched gold-standard clinical trial results, with digital coaching acting as a measurable multiplier. ...
2026-04-22 11:00
4245
Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D projects for the development of drugs for malaria and neglected tropical diseases (NTDs).2 Investment of a...
2026-04-22 10:00
3523
Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, includi...
2026-04-22 08:59
5669
Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
SHANGHAI, April 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment ...
2026-04-22 08:00
6180
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Adminis...
2026-04-21 10:00
5490
Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myelom...
2026-04-20 18:45
3718
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 310 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Noah Holdings Limited Announces Changes to the Board and Board Committees
2026-08-29 04:30
7430